COVID-19 疫苗接种后的精神科不良事件:韩国首尔基于人群的队列研究
该研究从韩国国民健康保险服务理赔数据库随机抽取首尔居民50%(n=2,027,353),按是否接种COVID-19疫苗分组,评估接种后1周、2周、1个月和3个月精神科不良事件的累积发病率。接种组抑郁、焦虑/分离/应激相关及躯体形式障碍、睡眠障碍的累积发病率高于未接种组,而精神分裂症和双相障碍的累积发病率低于未接种组。接种后抑郁(HR 1.683 [95%CI 1.520-1.863])、焦虑/分离/应激相关及躯体形式障碍(HR 1.439 [95%CI 1.322-1.568])和睡眠障碍(HR 1.934 [95%CI 1.738-2.152])风险升高,精神分裂症(HR 0.231 [95%CI 0.164-0.326])和双相障碍(HR 0.672 [95%CI 0.470-0.962])风险降低。
要点
- 接种组抑郁、焦虑/分离/应激相关及躯体形式障碍、睡眠障碍3个月累积发病率高于未接种组。
- 接种后抑郁HR 1.683(95%CI 1.520-1.863),睡眠障碍HR 1.934(95%CI 1.738-2.152)。
- 接种组精神分裂症和双相障碍累积发病率低于未接种组,HR分别为0.231和0.672。
核心结论
- COVID-19疫苗接种增加抑郁、焦虑/分离/应激相关及躯体形式障碍和睡眠障碍的风险,同时降低精神分裂症和双相障碍的风险。
- 作者认为对精神科不良事件易感人群追加接种COVID-19疫苗需特别谨慎。
研究设计与样本
- 基于韩国国民健康保险服务理赔数据库于2021年1月1日随机抽取的首尔居民50%(n=2,027,353),按COVID-19疫苗接种与否分为两组。
- 评估接种后1周、2周、1个月和3个月每10,000人精神科不良事件的累积发病率,并计算接种人群的风险比(HR)及95%置信区间(CI)。
主要发现
- 接种组抑郁、焦虑/分离/应激相关及躯体形式障碍、睡眠障碍、性障碍在接种后3个月的累积发病率高于未接种组。
- 接种组精神分裂症和双相障碍的累积发病率低于未接种组。
- 抑郁HR 1.683(95%CI 1.520-1.863),焦虑/分离/应激相关及躯体形式障碍HR 1.439(95%CI 1.322-1.568),睡眠障碍HR 1.934(95%CI 1.738-2.152)。
- 精神分裂症HR 0.231(95%CI 0.164-0.326),双相障碍HR 0.672(95%CI 0.470-0.962)。
临床怎么用
- 作者认为对精神科不良事件易感人群追加接种COVID-19疫苗需特别谨慎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Evidence has suggested an increased risk of psychiatric manifestations following viral infections including coronavirus disease-2019 (COVID-19). However, psychiatric adverse events (AEs) after COVID-19 vaccination, which were documented in case reports and case series, remain unclear. This study is aimed to investigate the psychiatric AEs after COVID-19 vaccination from a large population-based cohort in Seoul, South Korea. We recruited 50% of the Seoul-resident population randomly selected from the Korean National Health Insurance Service (KNHIS) claims database on 1, January, 2021. The included participants (n = 2,027,353) from the Korean National Health Insurance Service claims database were divided into two groups according to COVID-19 vaccination. The cumulative incidences per 10,000 of psychiatric AEs were assessed on one week, two weeks, one month, and three months after COVID-19 vaccination. Hazard ratios (HRs) and 95% Confidence interval (CIs) of psychiatric AEs were measured for the vaccinated population. The cumulative incidence of depression, anxiety, dissociative, stress-related, and somatoform disorders, sleep disorders, and sexual disorders at three months following COVID-19 vaccination were higher in the vaccination group than no vaccination group. However, schizophrenia and bipolar disorders showed lower cumulative incidence in the vaccination group than in the non-vaccinated group. Depression (HR [95% CI] = 1.683 [1.520-1.863]), anxiety, dissociative, stress-related, and somatoform disorders (HR [95% CI] = 1.439 [1.322-1.568]), and sleep disorders (HR [95% CI] = 1.934 [1.738-2.152]) showed increased risks after COVID-19 vaccination, whereas the risks of schizophrenia (HR [95% CI] = 0.231 [0.164-0.326]) and bipolar disorder (HR [95% CI] = 0.672 [0.470-0.962]). COVID-19 vaccination increased the risks of depression, anxiety, dissociative, stress-related, and somatoform disorders, and sleep disorders while reducing the risk of schizophrenia and bipolar disorder. Therefore, special cautions are necessary for administering additional COVID-19 vaccinations to populations vulnerable to psychiatric AEs.
引用
- Kim HJ, Kim MH, Choi MG, et al. Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea. Mol Psychiatry. 2024. PMID: 38834668. doi:10.1038/s41380-024-02627-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。